- Graduate School - Harvard T.H. Chan School of Public Health (2012-2013), Quantitative Methods
- Graduate School - Columbia University Mailman School of Public Health (2017-2019), Epidemiology
- Medical School - University of Michigan Medical School (2008-2014)
- Residency - Cleveland Clinic Foundation (2014-2017), Internal Medicine
- Fellowship - Beth Israel Deaconess Medical Center (2019-2022), Hematology Oncology
![Adeel Khan, M.D.](https://s3-us-west-2.amazonaws.com/utsw-patientcare-web-production/original_images/khan-adeel-212197-400x400.png)
Adeel Khan, M.D.
Director of Myeloma Epidemiology Research | Clinical Director of Monoclonal Gammopathy Precursor Clinic
- Internal Medicine - Hematology/Oncology
- Myeloma Treatment
- Waldenström Macroglobulinemia
New Patient Appointment Accepting Virtual Visits or 214-645-4673
Biography
Adeel Khan, M.D., M.P.H., M.S., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern Medical Center and a member of its Division of Hematology and Oncology. He is also an Assistant Professor in the Peter O’Donnell Jr. School of Public Health. He specializes in myeloma, amyloidosis, and Waldenström macroglobulinemia and serves as the Director of Myeloma Epidemiology Research and Clinical Director of the Monoclonal Gammopathy Precursor Clinic.
Dr. Khan earned his medical degree with special distinction at the University of Michigan in Ann Arbor, Michigan, while also obtaining a master’s degree in public health from Harvard University. He performed a residency in internal medicine at the Cleveland Clinic and Lerner College of Medicine in Cleveland, Ohio. After serving as a hospitalist at Massachusetts General Hospital and an instructor at Harvard Medical School and concurrently obtaining a master's degree in epidemiology from Columbia University, he gained advanced training in hematology and oncology through a fellowship at Beth Israel Deaconess Medical Center and Harvard Medical School.
Board certified in internal medicine and hematology, he joined the UT Southwestern faculty in 2022.
Dr. Khan’s research interests include myeloma and other monoclonal gammopathies, as well as cancer epidemiology. He has delivered numerous presentations at large national conferences and published peer-reviewed articles related to his areas of expertise.
He is a member of the American Society of Hematology, the American Society of Clinical Oncology, the American College of Physicians, and the American Public Health Association.
Education & Training
Professional Associations & Affiliations
- American College of Physicians
- American Public Health Association
- American Society of Clinical Oncology
- American Society of Hematology
Honors & Awards
- Excellence in Teaching 2017, Cleveland Clinic
- James H. Ware Award for Achievement in the Practice of Public Health 2013, Harvard University
- Trong D. Nguyen Memorial Award 2013, American Public Health Association
- Making a Difference Award 2011, University of Michigan
- Phi Beta Kappa 2007, University of Oklahoma
Books & Publications
-
Books
-
Oncologic issues of the aerodigestive tract in Principles and Practices of Hospital Medicine 2nd edition
Khan AM, Nwizu T (2016), New York, McGraw-Hill
-
Oncologic issues of the aerodigestive tract in Principles and Practices of Hospital Medicine 2nd edition
-
Publications
-
Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis.
Hoff FW, Banerjee R, Khan AM, McCaughan G, Wang B, Wang X, Roose J, Anderson LD, Cowan AJ, Rajkumar SV, Kaur G, Blood cancer journal 2024 Mar 14 1 52 -
Survival outcomes with warfarin compared with direct oral anticoagulants in cancer-associated venous thromboembolism in the United States: A population-based cohort study.
Khan AM, Chiasakul T, Redd R, Patell R, McCarthy EP, Neuberg D, Zwicker JI, PLoS medicine 2022 May 19 5 e1004012 -
A Cancer by Any Other Name.
Khan AM, The oncologist 2021 Jul -
Facing inadequacies: cultivating compassion from past failures.
Khan AM, The Lancet. Oncology 2021 06 22 6 762-763 -
Concerning trends in colorectal cancer in the wake of Chadwick Boseman's death.
Khan AM, Mucci LA, Journal of cancer policy 2020 Dec 26 100260 -
Heparin induced thrombocytopenia antibodies in Covid-19.
Patell R, Khan AM, Bogue T, Merrill M, Koshy A, Bindal P, Joyce R, Aird WC, Neuberg D, Bauer KA, Zwicker JI, American journal of hematology 2020 Oct 95 10 E295-E296 -
Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
Sehgal K, Piper-Vallillo AJ, Viray H, Khan AM, Rangachari D, Costa DB, Precision cancer medicine 2020 Jun 3
-
Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis.
Research
- Cancer epidemiology
- Clinical trials in hematologic malignancies
- Health outcomes and disparities
- Myeloma and other plasma cell dyscrasias
Clinical Focus
- Myeloma Treatment
- Waldenström Macroglobulinemia
- Amyloidosis
- General Hematology/Oncology
- Cancer Epidemiology
Results: 1 Locations
Blood Cancers/Transplant and Cellular Therapies Clinic
at Cancer Care Outpatient Building 6202 Harry Hines Blvd., 6th FloorDallas, Texas 75235 (214) 645-4673 Directions to Blood Cancers/Transplant and Cellular Therapies Clinic Parking Info for Blood Cancers/Transplant and Cellular Therapies Clinic
New Patient Appointment Accepting Virtual Visits or 214-645-4673